Announced Mon, 25 May · 12:10 IST

Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on May 25, 2026.

BETA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.6%1-day move

₹1350.70

prior close

₹1360.10

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.2+0.0+0.0+0.3+4.6+6.6+6.0+5.1+4.4+10.6+37.8+53.2+65.0—

Up moveDown movePending

AI summary

Beta Drugs Limited's board approved the allotment of 6,65,314 equity shares of ₹10 each to Healthquad Trust II and Inti Capital VCC - Inti Capital I. These shares were issued upon conversion of 6,65,314 Compulsory Convertible Debentures that were originally allotted on November 27, 2024. The conversion happened at a 1:1 ratio, meaning each CCD was converted into one equity share. This represents conversion of previous investments by these investors into equity, which will result in dilution for existing shareholders.

Likely market impact

Existing shareholders will face dilution as the equity share capital increases by 6,65,314 shares. The conversion signals that institutional investors (Healthquad Trust II and Inti Capital) have chosen to convert their debt instruments into equity, which could be seen as a positive sign of investor confidence in the company's prospects.